Dublin, Ireland, 25 April 2019 - ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been included in Forbes magazine's America's Best Employers list for 2019.

The ranking is based on an anonymous survey that polled 50,000 employees across America.

'We are proud Forbes has named ICON one of the best employers in America. For the third year in a row we are the highest ranked CRO, and one of the top 20 employers in the Drugs and Biotechnology industry overall,' commented Dr. Steve Cutler, Chief Executive Officer, ICON.

'We have a unique culture in ICON where our employees take pride in what we do, work together as one team in partnership with our customers to accelerate the development of drugs and devices that are saving the lives, and improving the quality of life, of patients right across the globe.

We are delighted that employees continue to recommend ICON as an excellent place to work and we will continue to work hard to ensure that our people can build successful and rewarding careers at ICON.'

Forbes 'America's Best Employers List' features the top 500 large employers in the US with more than 5,000 employees, and the top 500 midsize companies with 1,000 to 5,000 employees. This year, the independent, online survey was expanded from 30,000 to 50,000 US employees surveyed, at companies with at least 1,000 people, from across 38 industry sectors (up from 25 sectors the previous year).

The voluntary participation in online panels allowed employees to share their opinions about their employers openly and without any influence from their employer. Respondents were asked to rate their willingness to recommend their own companies on a scale of 0 to 10, and were also asked to name good and bad employers in industry sectors other than their own.

A full list of ICON's industry awards can be viewed at www.iconplc.com/awards.

About ICON plc

ICON plc is a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 90 locations in 37 countries and has approximately 13,680 employees.

Further information is available at http://www.iconplc.com

Attachments

  • Original document
  • Permalink

Disclaimer

ICON plc published this content on 25 April 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 25 April 2019 09:27:10 UTC